Search | Clinical Trials Finder

Conditions: Hypertension, Diabetic Nephropathies
Interventions: telmisartan, losartan; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 47
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Lancaster, California + 41 more

Conditions: Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions: Losartan, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 13
States / cities: Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more

Conditions: Pancreatic Cancer
Interventions: FOLFIRINOX, Losartan, Proton Beam Radiation; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumors, Metastatic Melanoma
Interventions: losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Eosinophilic Esophagitis
Interventions: Losartan Potassium; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 25 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: La Jolla, California • Chicago, Illinois • Cincinnati, Ohio

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 84 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Hypertension, High Blood Pressure
Interventions: Losartan, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions: Losartan Potassium; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 5 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions: Losartan, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma
Interventions: Losartan, Pembrolizumab, Stereotactic Body Radiation Therapy; Drug · Biological · Radiation
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Aurora, Colorado

Conditions: Arthrofibrosis
Interventions: Losartan; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease
Interventions: High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires; Drug · Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 2,476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 80
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more

Conditions: Stage 2 Systolic Hypertension
Interventions: valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions: Pharmacological Treatment; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 59 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Louisville, Kentucky • Omaha, Nebraska • New York, New York + 3 more

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: Paricalcitol, Hydroxychloroquine, Losartan, Neoadjuvant therapy and surgery only (Control); Combination Product · Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Colitis, Ulcerative, Crohn Disease
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions: Losartan; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Losartan; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bicuspid Aortic Valve, Thoracic Aortic Aneurysm
Interventions: Cozaar; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertension, Aging, Sedentary Lifestyle
Interventions: Aerobic exercise, Perindopril, Losartan, HCTZ; Behavioral · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Birmingham, Alabama • Orlando, Florida

Conditions: Diabetic Nephropathy
Interventions: Sulodexide, Placebo; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 968 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: nebivolol, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 75
States / cities: Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more

Search by objective public record fields.

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Losartan for Patients With COVID-19 Requiring Hospitalization

Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

N-of-1 Trials for Blood Pressure Medications in Adults

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

Efficacy of Losartan in Preventing Progression of COPD

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

Remission From Stage D Heart Failure

PHL Treatment in Pancreatic Cancer

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

The Effect of Losartan in Bicuspid Aortic Valve Patients

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

Effect of Sulodexide in Overt Diabetic Nephropathy

Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients